Overlap syndromes of autoimmune hepatitis: Diagnosis and treatment;Diagnóstico y tratamiento de los síndromes de sobreposición de hepatitis autoinmune

Revista de Gastroenterologia de Mexico

Volumn 80, Issue 2, 2015, Pages 150-159

  Aguilar Najera O ^a   Velasco Zamora, J A ^a   Torre, A ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Autoimmune hepatitis; Overlap; Primary biliary cirrhosis; Primary sclerosing cholangitis; Variants

Indexed keywords

AUTOIMMUNE HEPATITIS; CHOLANGITIS, SCLEROSING; CHOLESTASIS; COMPLICATION; DIFFERENTIAL DIAGNOSIS; HUMAN; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; SYNDROME;

CHOLANGITIS, SCLEROSING; CHOLESTASIS; DIAGNOSIS, DIFFERENTIAL; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; SYNDROME;

EID: 84944728638     PISSN: 03750906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rgmx.2015.04.001     Document Type: Short Survey

References (53)

1. Dhiman P, Malhotra S. Overlap syndromes: An emerging diagnostic and therapeutic challenge. Saudi J Gastroenterol. 2014;20:342-9.
2. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193-213.
3. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009;50:291-308.
4. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660-78.
5. Chazouillères O, Wendum D, Serfaty L, et al. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol. 2006;44:400-6.
6. Donaldson PT. Genetics of liver disease: Immunogenetics and disease pathogenesis. Gut. 2004;53:599-608.
7. Trivedi PJ, Hirschfield GM. Review article: Overlap syndromes and autoimmune liver disease. Aliment Pharmacol Ther. 2012;36:517-33.
8. Czaja AJ. Diagnosis and management of the overlap syndromes of autoimmune hepatitis. Can J Gastroenterol. 2013;27: 417-23.
9. Chan AW, Quaglia A, Haugk B, et al. Atlas of liver pathology. New York: Springer Science Business Media; 2014.
10. Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54:374-85.
11. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J Hepatol. 2009;51:237-67.
12. Rust C, Beuers U. Overlap syndromes among autoimmune liver diseases. World J Gastroenterol. 2008;14:3368-73.
13. Schramm C, Lohse AW. Overlap syndromes of cholestatic liver diseases and auto-immune hepatitis. Clin Rev Allergy Immunol. 2005;28:105-14.
14. Haldar D, Hirschfield GM. Overlap syndrome: A real syndrome. Clin Liver Dis. 2014;3:43-7.
15. Bunchorntavakul C, Reddy KR. Diagnosis and management of overlap syndromes. Clin Liver Dis. 2015;19:81-97.
16. Chazouillères O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis/autoimmune hepatitis overlap syndrome: Clinical features and response to therapy. Hepatology. 1998;28: 296-301.
17. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology. 1998;28:360-5.
18. O'Brien C, Joshi S, Feld JJ, et al. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology. 2008;48:550-6.
19. Montano-Loza AJ, Carpenter HA, Czaja AJ. Frequency, behavior, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis. J Clin Gastroenterol. 2008;42:1047-53.
20. Kuiper EM, Zondervan PE, van Buuren HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol. 2010;8:530-4.
21. Floreani A, Franceschet I, Cazzagon N. Primary biliary cirrhosis: Overlaps with other autoimmune disorders. Semin Liver Dis. 2014;34:352-60.
22. Muratori P, Granito A, Pappas G, et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol. 2009;104:1420-5.
23. Donaldson P, Doherty D, Underhill J, et al. The molecular genetics of autoimmune liver disease. Hepatology. 1994;20:225-39.
24. Coss-Adame E, Granados J, Uribe M, et al. Does HLA-DR7 differentiate the overlap syndrome of autoimmune hepatitis/ primary biliary cirrhosis (AIH-PBC) from those with autoimmune hepatitis type 1. Ann Hepatol. 2011;10:28-32.
25. Zepeda-Gomez S, Montano-Loza AJ, Zapata-Colindres JC, et al. HLA-DR allele frequencies in mexican mestizos with autoimmune liver diseases including overlap syndromes. Immunol Invest. 2009;38:276-83.
26. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48:871-7.
27. Czaja AJ. Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis. Aliment Pharmacol Ther. 2014;39:385-406.
28. Yoshioka Y, Taniai M, Hashimoto E, et al. Clinical profile of primary biliary cirrhosis with features of autoimmune hepatitis: Importance of corticosteroid therapy. Hepatol Res. 2014;44:947-55.
29. Silveira MG, Talwalkar JA, Angulo P, et al. Overlap of autoimmune hepatitis and primary biliary cirrhosis: Long-term outcomes. Am J Gastroenterol. 2007;102:1244-50.
30. Jung HE, Jang JY, Jeong SW, et al. Prognostic indicators in primary biliary cirrhosis: Significance of revised IAHG (International Autoimmune Hepatitis Group) score. Clin Mol Hepatol. 2012;18:375-82.
31. Joshi S, Cauch-Dudek K, Wanless IR, et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology. 2002;35:409-13.
32. Czaja A. The overlap syndromes of autoimmune hepatitis. Dig Dis Sci. 2013;58:326-43.
33. Kingham JG, Abbasi A. Co-existence of primary biliary cirrhosis and primary sclerosisng colangitis: A rare overlap syndrome put in perspective. Eur J Gastroenterol Hepatol. 2005;17:1077-80.
34. Czaja AJ. Cholestatic phenotypes of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2014;12:1430-8.
35. Abdalian R, Dhar P, Jhaveri K, et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: Evaluating the role of routine magnetic resonance imaging. Hepatology. 2008;47:949-57.
36. Lewin M, Vilgrain V, Ozenne V, et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: A prospective magnetic resonance imaging and histological study. Hepatology. 2009;50:528-37.
37. Al-Chalabi T, Portmann BC, Bernal W, et al. Autoimmune heptitis overlap síndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther. 2008;28:209-20.
38. Lüth S, Lohse A, Kanzler S, et al. Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. J Clin Gastroenterol. 2009;43:75-80.
39. Hyslop WB, Kierans AS, Leonardou P, et al. Overlap syndrome of autoimmune chronic liver diseases: MRI findings. J Magn Reson Imaging. 2010;31:282-9.
40. Floreani A, Rizzotto ER, Ferrara F, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol. 2005;100:1516-22.
41. Lindor K, Kowdley K, Luketic V, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50:808-14.
42. Baven-Pronk AM, van Hoek B, Coenraad MJ, et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther. 2011;34:335-43.
43. Karlsen TH, Franke A, Melum E, et al. Genomewide association analysis in primary sclerosing cholangitis. Gastroenterology. 2010;138:1102-11.
44. Czaja AJ, Carpenter HA, Santrach PJ, et al. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology. 2000;31:1231-8.
45. Olsson R, Glaumann H, Almer S, et al. High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur J Intern Med. 2009;20:190-6.
46. Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4- associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134:706-15.
47. Mayo MJ. Cholestatic liver disease overlap syndromes. Clin Liver Dis. 2013;17:243-53.
48. Silveira MG. IgG4-associated cholangitis. Clin Liver Dis. 2013;17:255-68.
49. Alswat K, Al-Harthy N, Mazrani W, et al. The spectrum of sclerosing cholangitis and the relevance of IgG4 elevations in routine practice. Am J Gastroenterol. 2012;107:56-63.
50. Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006;101:2070-5.
51. Bhamidimarri KR, Schiff E. Drug-induced cholestasis. Clin Liver Dis. 2013;17:519-31.
52. Bhanji RA, Mason AL, Girgis S, et al. Liver transplantation for overlap síndromes of autoimmune liver diseases. Liver Int. 2013;33:210-9.
53. Yamashiki N, Sugawara Y, Tamura S, et al. Living-donor liver transplantation for autoimmune hepatitis and autoimmune hepatitis-primary biliary cirrhosis overlap syndrome. Hepatol Res. 2012;42:1016-23.